Jay Skyler, MD, MACP
Dr. Skyler is currently Professor of Medicine, Pediatrics, and Psychology in the Division of Endocrinology, Diabetes, and Metabolism at the University of Miami, Deputy Director for Clinical Research and Academic Programs at the Diabetes Research Institute, University of Miami, and Adjunct Professor of Pediatrics at the Barbara Davis Center for Childhood Diabetes, University of Colorado. For 22 years, Dr. Skyler was Study Chairman for the National Institutes of Health (NIH)-sponsored Diabetes Prevention Trial for T1DM (DPT-1) and its successor the NIH T1DM TrialNet Clinical Trials Study Group (TrialNet), clinical trials networks aimed at preventing T1D or interdicting the T1D disease process. Dr. Skyler is closely involved with many scientific societies and has served as President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation; and Vice-President of the International Diabetes Federation. He was founding Editor-in-Chief of Diabetes Care and founding Scientific Editor of the International Diabetes Monitor, and currently is Senior Editor of Diabetes Technology & Therapeutics.
Dr. Skyler is a 1969 graduate of Jefferson Medical College. He did postgraduate training at Duke University and NIH.
Howard Weiner, MD
Howard L. Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners MS Center and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital in Boston. He has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer’s disease, ALS, stroke and brain tumors. He has also pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of anti-CD3 to induce regulatory T cells for the treatment of these diseases. He is the author of the book CURING MS and the award winning film documentary WHAT IS LIFE? THE MOVIE. In 2004, Harvard Medical School honored him with the establishment of the Howard L. Weiner Professorship of Neurologic Diseases.
Dr. Weiner graduated from the University of Colorado School of Medicine, completed residency at Beth Israel Deaconess Medical Center and Harvard-Longwood NeurologyTraining Program, prior to fellowships at Harvard Medical School, Massachusetts General Hospital, Colorado Multiple Sclerosis Society, and University of Colorado.
Betty Diamond, MD
Dr. Betty Diamond graduated with a BA from Harvard University and an MD from Harvard Medical School. She performed a residency in internal medicine at Columbia Presbyterian Medical Center and received postdoctoral training in immunology at the Albert Einstein College of Medicine.
Dr. Diamond has headed the rheumatology divisions at Albert Einstein School of Medicine and at Columbia University Medical Center. She also directed the Medical Scientist Training Program at Albert Einstein School of Medicine for many years. She is currently head of the Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases at The Feinstein Institutes for Medical Research and director of the PhD and MD/PhD programs of the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
A former president of the American Association of Immunology, Dr. Diamond has also served on the Board of Directors of the American College of Rheumatology and the Scientific Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Dr. Diamond is a fellow of the American Association for the Advancement of Science (AAAS) and a member of the National Academy of Medicine.
Edwin Liu, MD
Dr. Edwin Liu is Taplin Endowed Chair for Celiac Disease, Director, Colorado Center for Celiac Disease and Professor of Pediatrics at the University of Colorado School of Medicine and Children’s Hospital Colorado. His special area of interest in celiac disease relates to high-risk and general population screening. At Children’s Hospital Colorado since 1999, his research in the laboratory of Dr. George Eisenbarth studied potential vaccine therapies using insulin autoantigens for type 1 diabetes, and also learning about autoantibody assays for celiac disease. Dr. Liu has been involved in the large prospective Type 1 Diabetes and Celiac Disease birth cohort studies DAISY (Diabetes Autoimmunity Study of the Young) and the TEDDY (The Environmental Determinants of Diabetes in the Young) studies. As director of the Colorado Center for Celiac Disease, he treats individuals with celiac disease and gluten-related disorders. Dr. Liu received his MD from the Boston University School of Medicine